The FDA has approved a new once-weekly birth control patch that delivers less estrogen than the patch already on the market, and the approval comes with a restriction that will determine eligibility for a large share of American women.
Gwyn Lo, from Viatris, is a combined hormonal contraceptive patch approved on July 29 for the prevention of pregnancy in women with a body mass index below 30 kg/m2. It is contraindicated in women with a BMI of 30 or above.
That single criterion is the most consequential detail in the approval, and it is the one a reader needs before anything else. Roughly four in ten U.S. women have a BMI in the range the label excludes.
What Is Actually New Here
The hormones are not new. Gwyn Lo contains norelgestromin and ethinyl estradiol, the same combination in Xulane, the weekly patch Viatris already sells. The approval came through the FDA's 505(b)(2) pathway, which is used for products that build on data for an already approved drug rather than for entirely new molecules.
What changed is the dose, and it moved in both directions. Gwyn Lo delivers 20 micrograms of ethinyl estradiol per day, compared with 35 micrograms in Xulane. It also delivers 220 micrograms of norelgestromin per day, compared with 150 micrograms. So the estrogen is lower by roughly 40%, while the progestin is higher.
Most coverage will report the lower estrogen and stop there. The progestin increase belongs in the same sentence, because the two hormones carry different side effect profiles and a patient weighing options should know both numbers moved.
One further caution about the word low. Patch and pill doses are not directly comparable, because hormones absorbed through skin bypass the first pass through the liver and produce a different exposure pattern than a swallowed tablet. A 20 microgram patch is not equivalent to a 20 microgram pill, and anyone switching between forms should ask a clinician rather than compare the numbers on the box.
Philippe Martin, Viatris chief research and development officer, described the product in the company's announcement as "a discreet option for women seeking a reversible, non-invasive, once-weekly contraception patch." That is the manufacturer's framing of its own product.
What the Trial Showed
Approval rested on the Phase 3 Luminous study, which enrolled women aged 18 to 35 with a BMI below 30 and followed them across a year of use.
The primary measure was the Pearl Index, which counts pregnancies per 100 woman-years of exposure. Gwyn Lo's was 4.14, with a 95% confidence interval of 2.77 to 5.95. In plain terms, roughly four pregnancies occurred for every 100 women using the patch for a year in the efficacy evaluable population.
Readers should resist comparing that figure directly against numbers quoted for other methods. Pearl Index results vary with how a trial defines its population, how closely participants are monitored, and which cycles are counted, so figures from separate trials are not interchangeable. What can be said is that this is in the general range reported for combined hormonal contraceptives and is higher than the rates reported for long-acting methods such as implants and intrauterine devices.
Adhesion held up better than the patch category's reputation suggests. Of 39,790 patches applied during the trial, 1.3% detached completely. Four Phase 1 studies tested delivery under sauna, whirlpool, treadmill exercise and cold water immersion.
The most common side effects, each reported by 2% or more of participants, were application site irritation, redness and itching, bleeding between periods, heavy withdrawal bleeding and nausea. Unscheduled bleeding or spotting was common early and eased over time, falling from 34.5% of participants in the first cycle to 20.0% by the thirteenth.
One methodological point matters for interpretation. Contraceptive efficacy trials of this type are conventionally single-arm, without a comparator group, because randomizing participants to a placebo is not ethical when pregnancy is the outcome. That is standard for the field, but it means these results were not measured against another patch or pill in the same study.
Who Should Not Use It
The label carries limits that go beyond the BMI restriction, and combined hormonal contraceptives as a class carry an FDA boxed warning about cigarette smoking and cardiovascular risk.
Gwyn Lo is contraindicated in women who smoke and are over 35, because of an increased risk of serious cardiovascular events. It is contraindicated at a BMI of 30 or above, and the labeling notes that the risk of venous thromboembolism may be greater in women above that threshold.
The broader class contraindications apply to anyone considering this patch: a personal history of blood clots, stroke or heart attack, certain migraine patterns, some inherited clotting disorders, liver disease or liver tumors, breast cancer, uncontrolled high blood pressure, and diabetes with vascular complications. Patch labeling in this class also notes reduced effectiveness in women weighing 90 kilograms or more.
None of that makes the patch unsafe for the population it was approved for. It means eligibility here is narrower than for many contraceptive options, and the screening conversation is not a formality.
Anyone who develops sudden shortness of breath, chest pain, severe leg pain or swelling, sudden severe headache, vision changes, or weakness on one side of the body while using any combined hormonal contraceptive should seek emergency care.
What Families and Patients Should Do Now
There is nothing to do immediately, because the product is not on pharmacy shelves. Viatris said it expects Gwyn Lo to be commercially available later this year and has not announced a date or a price.
For someone who might want it, the useful preparation is a clinical conversation rather than a pharmacy call. Worth raising: whether a combined hormonal method is appropriate at all given personal and family history of clots, migraine, blood pressure and smoking status; whether the lower estrogen dose addresses a specific problem experienced on a current method; and how the patch compares with options that do not depend on weekly adherence.
Anyone whose BMI is 30 or above should know this particular product is not an option under its label, and that the conversation should move to other methods rather than to a workaround.
Cost and coverage are unresolved. Most insurance plans are required to cover FDA-approved contraceptive methods without cost sharing, but newly launched brand products frequently sit outside a plan's preferred tier at first and may require prior authorization or a documented reason another method did not work. That is worth asking about before a prescription is written.
Nobody should stop or change a current contraceptive in anticipation of switching. Gaps in coverage between methods are how unintended pregnancies happen.
What Happens Next
The company said it will give further commercial detail on its next financial results call. The open questions are launch timing, list price, formulary placement, and whether payers treat it as interchangeable with the existing higher estrogen patch.
The bottom line: the FDA approved Gwyn Lo, a weekly patch delivering less estrogen and more progestin than the existing norelgestromin patch, for women with a BMI under 30. Women who want a weekly method and have had estrogen-related side effects on another product are the group most likely to be interested. The reasonable step is a screening conversation with a clinician, not a wait for the pharmacy. The central uncertainty is price and coverage.
Frequently Asked Questions
What is Gwyn Lo? A once weekly combined hormonal contraceptive patch containing norelgestromin and ethinyl estradiol, approved July 29, 2026, for preventing pregnancy in women with a BMI under 30 kg/m2.
How is it different from the patch already available? It delivers 20 micrograms of ethinyl estradiol per day instead of 35, and 220 micrograms of norelgestromin instead of 150. The estrogen dose is lower, and the progestin dose is higher.
Who cannot use it? Women with a BMI of 30 or above, and women who smoke and are over 35. Class contraindications include a history of blood clots, stroke, certain migraines, liver disease, and breast cancer.
How is it used? One patch is applied weekly for three consecutive weeks, followed by one patch-free week.
How effective was it? The Pearl Index was 4.14, about four pregnancies per 100 women using it for a year. Figures from different trials are not directly comparable.
Does the patch fall off? In the trial, 1.3% of nearly 40,000 patches detached completely. Delivery held under sauna, whirlpool, exercise, and cold water conditions.
When can I get it, and what will it cost? Viatris expects availability later in 2026. No price or coverage information has been released.
Should I switch from my current method? Discuss it with a clinician, and do not stop a current method before a new one is in hand.
